ETF Managers Group’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-78,523
| Closed | -$1.89M | – | 828 |
|
|
2021
Q1 | $1.89M | Buy |
78,523
+11,032
| +16% | +$205K | 0.03% | 198 |
|
|
2020
Q4 | $980K | Buy |
67,491
+5,996
| +10% | +$79.5K | 0.02% | 240 |
|
|
2020
Q3 | $861K | Buy |
61,495
+3,053
| +5% | +$46.7K | 0.03% | 224 |
|
|
2020
Q2 | $794K | Buy |
58,442
+19,577
| +50% | +$199K | 0.03% | 207 |
|
|
2020
Q1 | $158K | Buy |
38,865
+3,984
| +11% | +$18.7K | 0.01% | 493 |
|
|
2019
Q4 | $166K | Buy |
34,881
+8,024
| +30% | +$44.3K | 0.01% | 526 |
|
|
2019
Q3 | $162K | Buy |
26,857
+302
| +1% | +$1.89K | 0.01% | 498 |
|
|
2019
Q2 | $169K | Buy |
+26,555
| New | +$187K | 0.01% | 496 |
|
|
2018
Q2 | – | Sell |
-5,480
| Closed | -$28K | – | 618 |
|
|
2018
Q1 | $28K | Buy |
5,480
+684
| +14% | +$3.4K | ﹤0.01% | 541 |
|
|
2017
Q4 | $22K | Buy |
4,796
+684
| +17% | +$4.12K | ﹤0.01% | 530 |
|
|
2017
Q3 | $40K | Buy |
4,112
+368
| +10% | +$3.82K | ﹤0.01% | 454 |
|
|
2017
Q2 | $44K | Buy |
+3,744
| New | +$47.9K | ﹤0.01% | 502 |
|
|
2016
Q1 | $57K | Buy |
+4,429
| New | +$24.7K | 0.04% | 117 |
|
ETF Managers Group's GNMK Position: Q2 2021 in Review
ETF Managers Group sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 78,523 shares — an estimated $1.89M sold.
ETF Managers Group first reported a position in GNMK in Q1 2016 and held it in 13 quarters. The position peaked at $1.89M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- ETF Managers Group reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- ETF Managers Group sold 78,523 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.89M.
- ETF Managers Group first reported a position in GenMark Diagnostics, Inc in Q1 2016 and held it in 13 quarters.
- ETF Managers Group's GenMark Diagnostics, Inc position peaked at $1.89M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on ETF Managers Group's 13F filing for Q2 2021, filed 16 Aug 2021.